Skip to main content

Irreversible Pulpitis

0
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Alliance Pharmaceuticals
1 program
Bite Force MeasurementsN/A1 trial
Active Trials
NCT06843525Recruiting112Est. Nov 2026
Septodont
SeptodontFrance - Saint-Maur-des-Fosses
1 program
Selective Caries Removal with Biodentine™N/A1 trial
Active Trials
NCT04807244Unknown249Est. Sep 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Alliance PharmaceuticalsBite Force Measurements
SeptodontSelective Caries Removal with Biodentine™

Clinical Trials (2)

Total enrollment: 361 patients across 2 trials

Bite Force Measurements

Start: May 2025Est. completion: Nov 2026112 patients
N/ARecruiting
NCT04807244SeptodontSelective Caries Removal with Biodentine™

Treatment of Deep Carious Lesions With Selective Caries Removal, Partial or Full Pulpotomy

Start: Apr 2021Est. completion: Sep 2025249 patients
N/AUnknown

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 361 patients
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.